To further validate whether CBX2 and CEP55 affect malignant cell stemness, we reanalyzed the public datasets related to HCC CSC and observed that CBX2 and CEP55 levels were higher in cancer stem cells that were CD133, ALDH, or CD44-labeled (Supplementary Figure 11C). The gene discussed is CEP55; the disease is hepatocellular carcinoma.